The global TNF inhibitors market size is expected to reach around US$ 53,745.37 Mn by 2026, in terms of revenue. It is expected to expand at a CAGR of 2.54% from 2019 to 2026. Expansion of the global TNF inhibitors market is driven by strong research & development and increasing awareness regarding usage of TNF inhibitors for the treatment of various rheumatic conditions during the forecast period.
This report on the TNF inhibitors market analyzes the current and future scenario of the global market. Rise in geriatric population, high prevalence of rheumatic diseases, and increase in patient preference for TNF inhibitors are major drivers of the global TNF inhibitors market.
The TNF inhibitors market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug, application, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global TNF Inhibitors Market.
Global TNF Inhibitors Market: Key Segments
The overall TNF Inhibitors Market can be segmented based on drug, application, distribution channel, and geography. Furthermore, in terms of drug, the market can be divided into adalimumab, certolizumab, etanercept, golimumab, and infliximab. The adalimumab segment is likely to account for a leading share of the global TNF inhibitors market during the forecast period, owing to wide usage of adalimumab in moderate to severe disease conditions. Based on application the market can be classified into rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis, and others. Based on distribution channel, the market can be segregated into hospital pharmacy, retail pharmacy, and online pharmacy. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2018 as the base year.
Global TNF Inhibitors Market: Regional Outlook
In terms of geography, the global TNF Inhibitors Market has been categorized into five major regions and the key countries in the respective region are: North America (U.S., Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, United Arab Emirates, Saudi Arabia, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2019 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2018 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global TNF inhibitors market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players operating in the global TNF inhibitors market include AbbVie, Inc., Janssen Biotech, Inc., UCB, Amgen, Inc., Pfizer, Inc., Samsung Bioepis, Biogen, Merck & Co., and Takeda Pharmaceutical Company.
The global TNF inhibitors market is segmented as given below:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global TNF Inhibitors Market: Market Snapshot
4. Market Overview
4.1. Global TNF Inhibitors Market: Overview
4.2. Global TNF Inhibitors Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Trends
4.4. Global TNF Inhibitors Market Size (US$ Mn) Forecast, 2019–2026
4.5. Global TNF Inhibitors Market Outlook
4.6. Porter’s Five Forces Analysis
4.7. Clinical trials pipeline analysis-TNF Inhibitors
4.8. Overview of Regulatory Framework for Development and Approval of Biosimilars
5. Global TNF Inhibitors Market Analysis, by Drug
5.1. Key Findings
5.2. Introduction
5.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Drug
5.4. Global TNF Inhibitors Market Value Forecast, by Drug
5.4.1. Adalimumab
5.4.2. Certolizumab
5.4.3. Etanercept
5.4.4. Golimumab
5.4.5. Infliximab
5.5. Global TNF Inhibitors Market Analysis, by Drug
6. Global TNF Inhibitors Market Analysis, by Application
6.1. Key Findings
6.2. Introduction
6.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Application
6.4. Global TNF Inhibitors Market Value Forecast, by Application
6.4.1. Rheumatoid Arthritis
6.4.2. Psoriasis
6.4.3. Inflammatory Bowel Disease
6.4.4. Ankylosing Spondylitis
6.4.5. Others
6.5. Global TNF Inhibitors Market Analysis, by Application
7. Global TNF Inhibitors Market Analysis, by Distribution channel
7.1. Key Findings
7.2. Introduction
7.3. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Distribution Channel
7.4. Global TNF Inhibitors Market Value Forecast, by Distribution channel
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Global TNF Inhibitors Market Analysis, by Distribution Channel
8. Global TNF Inhibitors Market Analysis, by Region
8.1. Global TNF Inhibitors Market Scenario, by Country
8.2. Global TNF Inhibitors Market Value Share and Attractiveness Analysis, by Region
8.3. Global TNF Inhibitors Market Value Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America TNF Inhibitors Market Analysis and Forecast
9.1. Key Findings
9.2. North America TNF Inhibitors Market Overview
9.3. North America TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
9.4. North America TNF Inhibitors Market Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America TNF Inhibitors Market Value Share Analysis, by Drug
9.6. North America TNF Inhibitors Market Forecast, by Drug
9.6.1. Adalimumab
9.6.2. Certolizumab
9.6.3. Etanercept
9.6.4. Golimumab
9.6.5. Infliximab
9.7. North America TNF Inhibitors Market Value Share Analysis, by Application
9.8. North America TNF Inhibitors Market Forecast, by Application
9.8.1. Rheumatoid Arthritis
9.8.2. Psoriasis
9.8.3. Inflammatory Bowel Disease
9.8.4. Ankylosing Spondylitis
9.8.5. Others
9.9. North America TNF Inhibitors Market Value Share Analysis, by Distribution channel
9.10. North America TNF Inhibitors Market Forecast, by Distribution channel
9.10.1. Hospital Pharmacy
9.10.2. Retail Pharmacy
9.10.3. Online Pharmacy
9.11. North America TNF Inhibitors Market Attractiveness Analysis
10. Europe TNF Inhibitors Market Analysis
10.1. Key Findings
10.2. Europe TNF Inhibitors Market Overview
10.3. Europe TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
10.4. Europe TNF Inhibitors Market Forecast, by Country
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe TNF Inhibitors Market Value Share Analysis, by Drug
10.6. Europe TNF Inhibitors Market Forecast, by Drug
10.6.1. Adalimumab
10.6.2. Certolizumab
10.6.3. Etanercept
10.6.4. Golimumab
10.6.5. Infliximab
10.7. Europe TNF Inhibitors Market Value Share Analysis, by Application
10.8. Europe TNF Inhibitors Market Forecast, by Application
10.8.1. Rheumatoid Arthritis
10.8.2. Psoriasis
10.8.3. Inflammatory Bowel Disease
10.8.4. Ankylosing Spondylitis
10.8.5. Others
10.9. Europe TNF Inhibitors Market Value Share Analysis, by Distribution channel
10.10. Europe TNF Inhibitors Market Forecast, by Distribution channel
10.10.1. Hospital Pharmacy
10.10.2. Retail Pharmacy
10.10.3. Online Pharmacy
10.11. Europe TNF Inhibitors Market Attractiveness Analysis
11. Asia Pacific TNF Inhibitors Market Analysis
11.1. Key Findings
11.2. Asia Pacific TNF Inhibitors Market Overview
11.3. Asia Pacific TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
11.4. Asia Pacific TNF Inhibitors Market Forecast, by Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Drug
11.6. Asia Pacific TNF Inhibitors Market Forecast, by Drug
11.6.1. Adalimumab
11.6.2. Certolizumab
11.6.3. Etanercept
11.6.4. Golimumab
11.6.5. Infliximab
11.7. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Application
11.8. Asia Pacific TNF Inhibitors Market Forecast, by Application
11.8.1. Rheumatoid Arthritis
11.8.2. Psoriasis
11.8.3. Inflammatory Bowel Disease
11.8.4. Ankylosing Spondylitis
11.8.5. Others
11.9. Asia Pacific TNF Inhibitors Market Value Share Analysis, by Distribution channel
11.10. Asia Pacific TNF Inhibitors Market Forecast, by Distribution channel
11.10.1. Hospital Pharmacy
11.10.2. Retail Pharmacy
11.10.3. Online Pharmacy
11.11. Asia Pacific TNF Inhibitors Market Attractiveness Analysis
12. Latin America TNF Inhibitors Market Analysis
12.1. Key Findings
12.2. Latin America TNF Inhibitors Market Overview
12.3. Latin America TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
12.4. Latin America TNF Inhibitors Market Forecast, by Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America TNF Inhibitors Market Value Share Analysis, by Drug
12.6. Latin America TNF Inhibitors Market Forecast, by Drug
12.6.1. Adalimumab
12.6.2. Certolizumab
12.6.3. Etanercept
12.6.4. Golimumab
12.6.5. Infliximab
12.7. Latin America TNF Inhibitors Market Value Share Analysis, by Application
12.8. Latin America TNF Inhibitors Market Forecast, by Application
12.8.1. Rheumatoid Arthritis
12.8.2. Psoriasis
12.8.3. Inflammatory Bowel Disease
12.8.4. Ankylosing Spondylitis
12.8.5. Others
12.9. Latin America TNF Inhibitors Market Value Share Analysis, by Distribution channel
12.10. Latin America TNF Inhibitors Market Forecast, by Distribution channel
12.10.1. Hospital Pharmacy
12.10.2. Retail Pharmacy
12.10.3. Online Pharmacy
12.11. Latin America TNF Inhibitors Market Attractiveness Analysis
13. Middle East & Africa TNF Inhibitors Market Analysis
13.1. Key Findings
13.2. Middle East & Africa TNF Inhibitors Market Overview
13.3. Middle East & Africa TNF Inhibitors Market Value Share and Attractiveness Analysis, by Country
13.4. Middle East & Africa TNF Inhibitors Market Forecast, by Country
13.4.1. South Africa
13.4.2. UAE
13.4.3. Saudi Arabia
13.4.4. Rest of Middle East and Africa
13.5. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Drug
13.6. Middle East & Africa TNF Inhibitors Market Forecast, by Drug
13.6.1. Adalimumab
13.6.2. Certolizumab
13.6.3. Etanercept
13.6.4. Golimumab
13.6.5. Infliximab
13.7. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Application
13.8. Middle East & Africa TNF Inhibitors Market Forecast, by Application
13.8.1. Rheumatoid Arthritis
13.8.2. Psoriasis
13.8.3. Inflammatory Bowel Disease
13.8.4. Ankylosing Spondylitis
13.8.5. Others
13.9. Middle East & Africa TNF Inhibitors Market Value Share Analysis, by Distribution channel
13.10. Middle East & Africa TNF Inhibitors Market Forecast, by Distribution channel
13.10.1. Hospital Pharmacy
13.10.2. Retail Pharmacy
13.10.3. Online Pharmacy
13.11. Middle East & Africa TNF Inhibitors Market Attractiveness Analysis
14. Competitive Landscape
14.1. Company Profiles
14.1.1. AbbVie, Inc.
14.1.1.1.1. Company Details
14.1.1.1.2. Business Overview
14.1.1.1.3. Financial Overview
14.1.1.1.4. Strategic Overview
14.1.1.1.5. SWOT Analysis
14.1.2. Janssen Biotech, Inc.
14.1.2.1.1. Company Details
14.1.2.1.2. Business Overview
14.1.2.1.3. Financial Overview
14.1.2.1.4. Strategic Overview
14.1.2.1.5. SWOT Analysis
14.1.3. Amgen, Inc.
14.1.3.1.1. Company Details
14.1.3.1.2. Business Overview
14.1.3.1.3. Financial Overview
14.1.3.1.4. Strategic Overview
14.1.3.1.5. SWOT Analysis
14.1.4. UCB Inc.
14.1.4.1.1. Company Details
14.1.4.1.2. Business Overview
14.1.4.1.3. Financial Overview
14.1.4.1.4. Strategic Overview
14.1.4.1.5. SWOT Analysis
14.1.5. Samsung Bioepis
14.1.5.1.1. Company Details
14.1.5.1.2. Business Overview
14.1.5.1.3. Financial Overview
14.1.5.1.4. Strategic Overview
14.1.5.1.5. SWOT Analysis
14.1.6. Biogen
14.1.6.1.1. Company Details
14.1.6.1.2. Business Overview
14.1.6.1.3. Financial Overview
14.1.6.1.4. Strategic Overview
14.1.6.1.5. SWOT Analysis
14.1.7. Merck & Co.
14.1.7.1.1. Company Details
14.1.7.1.2. Business Overview
14.1.7.1.3. Financial Overview
14.1.7.1.4. Strategic Overview
14.1.7.1.5. SWOT Analysis
14.1.8. Takeda Pharmaceutical Company
14.1.8.1.1. Company Details
14.1.8.1.2. Business Overview
14.1.8.1.3. Financial Overview
14.1.8.1.4. Strategic Overview
14.1.8.1.5. SWOT Analysis
14.1.9. Pfizer, Inc.
14.1.9.1.1. Company Details
14.1.9.1.2. Business Overview
14.1.9.1.3. Financial Overview
14.1.9.1.4. Strategic Overview
14.1.9.1.5. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers